levofloxacinstarry

starry  时间:2021-01-09  阅读:()
RegulatoryStoryGotomarketnewssectionCompanyCathayInternationalHoldingsLdTIDMCTIHeadlineZhejiangStarryPharmaceuticalCo.
,Ltd.
Released07:0016-Nov-2010Number2440W07RNSNumber:2440WCathayInternationalHoldingsLd16November2010CATHAYINTERNATIONALHOLDINGSLIMITEDProposedminorityinvestmentinZhejiangStarryPharmaceuticalCo.
,Ltd.
('Starry')CathayInternationalHoldingsLtd.
(LSE:CTI.
L)('Cathay'orthe'Company'),acompanyinvestingprimarilyinthegrowingpharmaceuticalandhealthcaresectorsinthePeople'sRepublicofChina('PRC'),announcestodaythat:·LansenPharmaceuticalHoldingsLimited(HKE:503.
HK)('Lansen'),theCompany'ssubsidiarylistedonthemainboardoftheHongKongExchange,hasannouncedtodaythatithasagreedthetermsforthepurchaseofa20%equityinterestinStarry('Lansen'sInvestment')fromanindependentthirdpartyforacashconsiderationofapproximatelyUS$24million;and·theCompanyhasagreedthetermsforthepurchaseofa1.
5%equityinterestinStarry(the'Company'sInvestment')fromthesameindependentthirdpartyforacashconsiderationofapproximatelyUS$1.
8million.
DetailsofthetransactionLansen'sInvestmentistobeeffectedpursuanttoanequitytransferagreement(the'LansenAgreement')underwhichLansenInvestments(HongKong)Limited('LSI'),anindirectwhollyownedsubsidiaryofLansen,hasagreedtopurchaseandMr.
LiewYewThoong(the'Vendor'),oneoftheexistingminorityshareholdersofStarry,hasagreedtosell,20%oftheregisteredcapitalofStarryforacashconsiderationofapproximatelyUS$24million(RMB160million).
TheCompany'sInvestmentistobeeffectedpursuanttoaseparateequitytransferagreement(the'CathayAgreement')underwhichFullKeenLimited('FKL')anindirectwholly-ownedsubsidiaryoftheCompany,hasagreedtopurchaseandtheVendorhasagreedtosell,1.
5%oftheregisteredcapitalofStarryforacashconsiderationofapproximatelyUS$1.
8million(RMB12million).
ZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
1of411/16/20103:03PMInformationonStarryStarryisasino-foreignequityjointventureincorporatedunderthelawsofthePRC.
Itisacompanyspecializingintheproductionofbulkpharmaceuticalsandintermediates.
ThetwocorebulkpharmaceuticalproductsofStarryareiohexolforX-CTnon-ioniccontrastagentsandlevofloxacinforantibiotics.
StarryisthelargestiohexolmanufacturerinthePRCandisexperiencedintheproductionmanagementandqualitycontrolofbulkpharmaceuticals.
SetoutbelowisasummaryoftheauditedfinancialresultsofStarryforthetwoyearsended31December2008and31December2009,whichwerepreparedinaccordancewiththePRCgenerallyacceptedaccountingprinciples:Yearended31December20092008EquivalentEquivalentRMB'000US$'000RMB'000US$'000Profitbeforetaxation57,9748,72532,8604,945Profitaftertaxation57,9748,72532,8604,945Grossassets549,49182,698467,79470,403Netassets199,70730,056139,05320,927ConsiderationTheconsiderationforLansen'sInvestmentisRMB160million(approximatelyUS$24million),whichshallbefundedthroughtheexistinginternalresourcesoftheLansengroup.
TheconsiderationfortheCompany'sInvestmentisRMB12million(approximatelyUS$1.
8million).
TheconsiderationwillbesatisfiedoutoftheCompany'sinternalresources.
Theconsiderationwasagreedafterarm'slengthnegotiationsbetweenLansen,theCompanyandtheVendor,takingintoconsideration,amongstotherthings,(i)thenetassetvalueofStarryasat31December2009;(ii)futureprospectsofthebusinessofStarry;(iii)theprospectsofthepharmaceuticalindustryinthePRCasawhole;and(iv)tradingpriceearningsmultiplesofStarry'smarketcomparablesinthePRC.
TheconsiderationpayablefortheCompany'sInvestmentandLansen'sInvestmentshallbesettledwithin10businessdaysofreceiptoftherelevantgovernmentapprovalinthePRCforthetransferoftheequityinterestsundertherespectiveagreement.
Iftherelevantgovernmentapprovalforthetransferoftheequityinterestsisnotreceivedwithin60daysfromthedateoftheapplicationforapproval(orsuchotherdateastheVendorandLSIorFKL,asthecasemaybe,mayagree)theLansenAgreementandtheCathayAgreementshalllapseandbeofnofurtherforceandeffect.
EffectofthetransactionontheCathaygroupandbenefitsofthetransactionThereasonsforandexpectedbenefitsofLansen'sInvestmentincludethefollowingmatters:·OneofLansen'sstrategiesistoexploreopportunities,throughbusinessalliancesoracquisitions,whichwouldexpanditsproductrangeofrheumaticspecialtydrugs,includingtheupstreambulkpharmaceuticalproductionforrheumaticspecialtydrugs.
TheboardofLansenbelievesthatLansen'sInvestmentprovidesLansenwithopportunitiestoparticipateintheupstreamZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
2of411/16/20103:03PMsupplybusinessinthepharmaceuticalindustryvaluechain.
Lansen'sInvestmentisofstrategicsignificancesinceLansen'sInvestmentwillallowittodevelopexperienceintheproductionmanagementandcontrolofbulkpharmaceuticalsforitsdrugsinthefuture.
·Theimpactonbulkpharmaceuticalsappeartobelesssubstantialthantheimpactondownstreampharmaceuticalproductsundertherecent"DrugPriceControlMeasures"discussionpaperpublishedbythePRCgovernment.
Lansen'sInvestmentwillachieveacertaindegreeofdiversificationofproductconcentrationrisk.
·Lansen'sboardbelievesthatLansen'sInvestmentisconsistentwithLansen'sbusinessobjectiveofestablishingandstrengtheningbusinessallianceswithpharmaceuticalcompanies.
LansenwillbenefitfromStarry'sexperienceinareasincludingrawmaterialsproductiontechnology,GMPcertification,costandqualitycontrol,andenvironmentalprotection.
LansenisnotexpectedtodevotesignificanthumanandmanagementresourcestoStarry'soperations.
·Lansen'sboardconsidersthatthetermsandconditionsoftheLansenAgreement,includingtheconsiderationthereof,arefairandreasonableandthattheenteringintooftheLansenAgreementisintheinterestsofLansenanditsshareholdersasawhole.
ForCathay,theCompany'sInvestmentisinlinewiththeintentionstatedintheCompany's2010interimreporttospecializeinthefastgrowingpharmaceutical,healthcareandenvironmentprotectionmarketsandtowidentheinvestmentscopeoftheCathayGrouptoincludepotentialminorityinvestmentpositions.
TheBoardofCathayconsidersthatthetermsandconditionsoftheCathayAgreement,includingtheconsiderationthereof,arefairandreasonableandthattheenteringintooftheCathayAgreementisintheinterestsoftheCompanyanditsshareholdersasawhole.
DetailsofkeyindividualsimportanttothebusinessofStarryMr.
HuJinsheng,56,founderandoneofthemajorshareholdersofStarry,hasbeeninthebusinessforthirtyyearsandpossessesextensiveexperienceinoperationalandfinancialmanagementissues.
Mr.
HuJinshengistheGeneralManagerofStarry.
Mr.
HuJian,thesonofMr.
HuJinsheng,isanothermajorshareholderofStarry.
Mr.
HuJianistheDeputyGeneralManagerofStarry.
EnquiriesCathayInternationalHoldingsLimited+85228289289JinyiLee/EricSiuBrunswick+44(0)2074045959JonColesCertainstatementsinthisannouncementareforward-lookingstatements.
ThesestatementsrelatetotheCathayGroup'sfutureprospects,developmentsandbusinessstrategies.
Forward-lookingstatementsareidentifiedbytheiruseoftermsandphrasessuchas"believe","could","envisage","estimate","intend","may","plan","will"orthenegativeofthose,variationsorcomparableexpressions,includingreferencestoassumptions.
Theforward-lookingstatementsinthisannouncementarebasedoncurrentexpectationsandaresubjecttorisksanduncertaintiesthatcouldcauseactualresultstodiffermateriallyfromthoseexpressedorimpliedbythosestatements.
Giventheserisksanduncertainties,potentialinvestorsshouldnotplaceanyrelianceonforward-lookingZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
3of411/16/20103:03PMstatements.
Theseforward-lookingstatementsspeakonlyasatthedateofthisannouncement.
NeithertheDirectorsnortheCompanyundertakeanyobligationtoupdateforward-lookingstatementsotherthanasrequiredbytheListingRules,DisclosureandTransparencyRules,applicablelegislationorbytherulesofanyothersecuritiesregulatoryauthority,whetherasaresultofnewinformation,futureeventsorotherwise.
ThisinformationisprovidedbyRNSThecompanynewsservicefromtheLondonStockExchangeENDMSCDMMMMVVRGGZGLondonStockExchangeplcisnotresponsibleforanddoesnotcheckcontentonthisWebsite.
Websiteusersareresponsibleforcheckingcontent.
Anynewsitem(includinganyprospectus)whichisaddressedsolelytothepersonsandcountriesspecifiedthereinshouldnotberelieduponotherthanbysuchpersonsand/oroutsidethespecifiedcountries.
Termsandconditions,includingrestrictionsonuseanddistributionapply.
2009LondonStockExchangeplc.
AllrightsreservedRegulatoryZhejiangStarryPharmaceuticalCo.
,Ltd.
-LondonStockExchangehttp://www.
londonstockexchange.
com/exchange/news/market-news/mar.
.
.
4of411/16/20103:03PM

日本CN2独立物理服务器 E3 1230 16G 20M 500元/月 提速啦

提速啦的来历提速啦是 网站 本着“良心 便宜 稳定”的初衷 为小白用户避免被坑 由赣州王成璟网络科技有限公司旗下赣州提速啦网络科技有限公司运营 投资1000万人民币 在美国Cera 香港CTG 香港Cera 国内 杭州 宿迁 浙江 赣州 南昌 大连 辽宁 扬州 等地区建立数据中心 正规持有IDC ISP CDN 云牌照 公司。公司购买产品支持3天内退款 超过3天步退款政策。提速啦的市场定位提速啦主...

friendhosting:(优惠55%)大促销,全场VPS降价55%,9个机房,不限流量

每年的7月的最后一个周五是全球性质的“系统管理员日”,据说是为了感谢系统管理员的辛苦工作....friendhosting决定从现在开始一直到9月8日对其全球9个数据中心的VPS进行4.5折(优惠55%)大促销。所有VPS基于KVM虚拟,给100M带宽,不限制流量,允许自定义上传ISO...官方网站:https://friendhosting.net比特币、信用卡、PayPal、支付宝、微信、we...

AkkoCloud(60元/月 ),英国伦敦CN2 1核 768 MB 内存 10 GB SSD 硬盘 600GB 流量 英国伦敦CN2 1核  1.5G  300Mbps

官方网站:https://www.akkocloud.com/AkkoCloud新品英国伦敦CN2 GIA已上线三网回程CN2 GIA 国内速度优秀.电信去程CN2 GIALooking Glass:http://lonlg.akkocloud.com/Speedtest:http://lonlg.akkocloud.com/speedtest/新品上线刚好碰上国庆节 特此放上国庆专属九折循环优惠...

starry为你推荐
.net虚拟主机.net虚拟主机空间怎么选择,国内虚拟主机哪家比较好,各有什么特色美国主机空间美国主机空间不限制内容吗域名备案查询如何查网站备案信息英文域名中文域名和英文域名有什么区别,越具体越好成都虚拟空间五星网络隶属于成都冠一科技有限公司,虚拟空间购买了不到一个月不能访问2次,质量真差啊!深圳网站空间深圳网站设计 哪家好一些?郑州虚拟主机虚拟主机哪个好点,用过的推荐下云南虚拟主机用哪家虚拟主机?(美橙互联还是西部数码)域名停靠域名停放是什么?中文域名中文域名有哪些?
域名批量查询 哈尔滨服务器租用 免费域名空间申请 美国独立服务器 荷兰服务器 国外服务器 512m 英文简历模板word 抢票工具 12u机柜尺寸 轻博 免费静态空间 php免费空间 一元域名 个人空间申请 lol台服官网 网站卫士 昆明蜗牛家 常州联通宽带 1元域名 更多